other material
confidence high
sentiment positive
materiality 0.85
LianBio's mavacamten meets primary endpoint in Phase 3 EXPLORER-CN trial; NDA accepted with Priority Review in China
LianBio
- EXPLORER-CN met primary endpoint: Valsalva LVOT gradient improvement from baseline to week 30 vs placebo (p<0.001).
- All secondary endpoints met, including resting LVOT gradient, NYHA class improvement, KCCQ-CSS, and LV mass index.
- Safety consistent with prior studies; no LVEF <50% requiring dose interruption.
- NDA for mavacamten accepted with Priority Review by China NMPA for symptomatic oHCM.
- LianBio to host analyst event May 1 to discuss topline data and China market opportunity.